REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has successfully closed its public offering of 4,260,000 common stock shares at $47.00 each, yielding approximately $230.3 million in gross proceeds after the underwriters' full option exercise for an additional 639,000 shares. This offering was managed by BofA Securities, Morgan Stanley, and Barclays. The shares were offered under a shelf registration statement effective since August 8, 2018. The funds raised will support REGENXBIO's ongoing gene therapy developments utilizing its proprietary NAV Technology Platform.

Positive

• The offering raised approximately $230.3 million in gross proceeds, enhancing liquidity for continued development.
• The exercise of the underwriters' option allows for additional funding, essential for advancing its gene therapy pipeline.

Negative

• Issuing additional shares may lead to potential dilution of existing shareholders.

ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its common stock at a price to the public of $47.00 per share, as well as the exercise in full of the underwriters' option to purchase 639,000 additional shares at the public offering price. Including the option exercise, the total gross proceeds to REGENXBIO are expected to be approximately $230.3 million, before deducting the underwriting discounts and commissions and estimated offering expenses.

BofA Securities, Morgan Stanley and Barclays acted as joint book-running managers of the offering. Raymond James acted as lead manager of the offering.

The securities described above were offered by REGENXBIO pursuant to a shelf registration statement on Form S-3 that was filed with the Securities and Exchange Commission (the "SEC") on August 8, 2018 (File No. 333-226691) and became automatically effective upon filing. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: BofA Securities at NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or by email at dg.prospectus_requests@baml.com; Morgan Stanley at Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014; or Barclays Capital Inc., c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, New York 11717 or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's offering of its common stock. REGENXBIO has based these forward-looking statements on its current expectations and assumptions as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, many of which are beyond the control of REGENXBIO. For a discussion of these risks, refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other filings with the SEC, which are available on the SEC's website at www.sec.gov. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301206847.html

SOURCE REGENXBIO Inc.

FAQ

What is the total amount raised in REGENXBIO's recent public offering?

REGENXBIO raised approximately $230.3 million in gross proceeds from its public offering.

How many shares were offered in REGENXBIO's public offering?

A total of 4,260,000 shares were offered, with an additional 639,000 shares from the underwriters' option.

What was the offering price for REGENXBIO's common stock?

The offering price for REGENXBIO's common stock was $47.00 per share.

Who managed REGENXBIO's public offering?

The public offering was managed by BofA Securities, Morgan Stanley, and Barclays.

What are the potential impacts of REGENXBIO's public offering on shareholders?

While the offering raises funds for development, it may also lead to dilution of existing shareholders.